2013-02-18 14:23:40 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Pharmarise Corporation and produced a Rating Update Report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal – SADIF Investment Analytics, announces a new Rating Update Report covering Pharmarise Corporation (2796). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Pharmarise Corporation investor.
Report Summary: Pharmarise Corporation is an above average quality company with a neutral outlook. Pharmarise Corporation has strong business growth and is run by efficient management. The trend in Pharmarise Corporation fair value exchange rate against its closest rated-competitor, Medical Ikkou Co., Ltd., has been appreciating over the past 2 weeks. When compared to its closest competitor, Pharmarise Corporation shows greater undervaluation and is equally likely to outperform the market.
The 3-page report breaks down the Total StockMark into its three components – business, management
and price, performing an in-depth analysis of Pharmarise Corporation for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.